CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells

Norihiko Kawamura; Keisuke Nimura; Hiromichi Nagano; Sohei Yamaguchi; Norio Nonomura; Yasufumi Kaneda

doi:10.18632/oncotarget.4293

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells

Norihiko Kawamura _, Keisuke Nimura, Hiromichi Nagano, Sohei Yamaguchi, Norio Nonomura and Yasufumi Kaneda

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:22361-22374. https://doi.org/10.18632/oncotarget.4293

Metrics: PDF 4621 views | HTML 5140 views | ?

Abstract

Norihiko Kawamura1,2, Keisuke Nimura1, Hiromichi Nagano1, Sohei Yamaguchi1, Norio Nonomura2, Yasufumi Kaneda1

1Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Osaka 565–0871, Japan

2Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565–0871, Japan

Correspondence to:

Keisuke Nimura, e-mail: [email protected]

Yasufumi Kaneda, e-mail: [email protected]

Keywords: NANOG, NANOGP8, gene knockout, CRISPR/Cas9, prostate cancer

Received: March 31, 2015 Accepted: June 03, 2015 Published: June 15, 2015

ABSTRACT

NANOG expression in prostate cancer is highly correlated with cancer stem cell characteristics and resistance to androgen deprivation. However, it is not clear whether NANOG or its pseudogenes contribute to the malignant potential of cancer. We established NANOG- and NANOGP8-knockout DU145 prostate cancer cell lines using the CRISPR/Cas9 system. Knockouts of NANOG and NANOGP8 significantly attenuated malignant potential, including sphere formation, anchorage-independent growth, migration capability, and drug resistance, compared to parental DU145 cells. NANOG and NANOGP8 knockout did not inhibit in vitro cell proliferation, but in vivo tumorigenic potential decreased significantly. These phenotypes were recovered in NANOG- and NANOGP8-rescued cell lines. These results indicate that NANOG and NANOGP8 proteins are expressed in prostate cancer cell lines, and NANOG and NANOGP8 equally contribute to the high malignant potential of prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4293

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells

Abstract